Publications
The Importance of Diversity of Supply in Rare Diseases Markets
23 January 2025
Rare disease medicine markets often rely on single suppliers, increasing the risk of shortages and limiting treatment options. Our report explores how supplier diversity can enhance healthcare resilience and drive innovation, with actionable recommendations for policymakers.
2023 OHE Annual Report to the Charity Commission
16 December 2024
We are pleased to submit our seventh submission to the Charity Commission for England and Wales since becoming a registered charity in December 2016.
Employer Costs from Respiratory Infections
16 December 2024
Our latest research shows respiratory infections cost UK businesses £44 billion a year. Workplace vaccination programs and health-focused policies could help boost productivity, reduce costs, and address health inequities.
Understanding societal preferences for priority by disease severity in England & Wales
14 November 2024
How does NICE’s severity modifier work? NICE implemented a new severity modifier in February 2022 as part of a wider update to its methods. Its aim…
A Spotlight on Haemophilia Therapies
3 October 2024
Pharmaceutical innovation is a key driver of improvements in health outcomes, quality of life and productivity for people with acute and chronic conditions.
The Cost of Drug Shortages
16 September 2024
Across the globe, drug shortages are becoming increasingly common.
Unlocking the Value of Combination Therapies
9 July 2024
Combination therapies (CTs) merge treatments with different mechanisms of action to achieve greater clinical benefits than the individual components alone. CTs are increasingly being used in oncology.
Inequalities in Dementia: Unveiling the Evidence and Forging a Path Towards Greater Understanding
26 June 2024
Our literature review suggests that there are more than 100 inequalities impacting on people living with dementia and their carers across multiple characteristics, circumstances, and in various parts of the health and care system. However, the current low availability and quality of data is a major barrier to accurately measuring these inequalities. With the expectation that 1 in 2 people will be affected by dementia during their lifetime, there is a pressing need for further research to inform future policy, research, and service interventions.
A Framework for Value-aligned Pricing of Combination Therapies
25 June 2024
Combination therapies can provide effective treatment options and improve patient outcomes. However, there are significant barriers to patient access to combination therapies, including the prevailing pricing models used in Europe.